Eli Lilly and Company Expands Lebanon, Indiana, Manufacturing Operations
06/02/2024
The investment will increase the company’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection. Initial operations are scheduled for the end of 2026.
“Lilly’s commitment to meeting the demand for our life-changing medicines goes beyond buildings and extends to improving education opportunities and upskilling a global workforce of the future,” said Edgardo Hernandez, executive vice president and president, Lilly Manufacturing Operations. “Academia is a critical partner to both industry and government as we work together to advance innovation in our state and communities around the globe.”
To support the project, the state will partner on infrastructure solutions – road improvements, water, electric and other utilities – as well as workforce development commitments and certain economic incentives tied to the company's achievement of investment and employment goals. The state's workforce development support includes the contribution of land, pending approval, for the construction of a learning and training center that will be part of the larger LEAP industrial development, along with a commitment to work with Lilly to raise capital for its completion.
"Lilly continues to play a transformational role in shaping Indiana's opportunity economy, and I couldn't be more proud about their pole position leadership in developing the LEAP Research and Innovation District in Lebanon, Indiana. Lilly has long been driving global innovation and economic growth that will be felt for decades here at home," noted Indiana Governor Eric J. Holcomb. "As an international company, headquartered in Indiana, Lilly had a world of options to consider before making this investment, and choosing Indiana once again reinforces the incredible environment we've cultivated and the talented workforce we have to carry Lilly's success forward. I can't wait to see the incredible benefits this investment leads to for patients around the world, knowing they were made in Indiana."
Since 2020, Lilly noted it has committed more than $16 billion to develop new manufacturing sites in the U.S. and Europe. New locations outside Indiana include; Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany.
Recent Project Announcements
Turner Industries Plans New Iberia-Port Allen, Louisiana, Nuclear Fabrication Operations
05/02/2026
Stella-Jones Corporation Expands Lincoln County, Tennessee, Operations
05/02/2026
Adrian Steel Company Expands Lenawee County, Michigan, Operations
05/02/2026
Pivot Bio Expands Hazelwood, Missouri, Operations
04/29/2026
Davis Timber Company Expands DeRidder, Louisiana, Manufacturing Operations
04/28/2026
Blevins Asphalt Expands Mount Vernon, Missouri, Maintenance Operations
04/28/2026
Niagara Bottling Plans Perth, New York, Production-Warehouse Operations
04/26/2026
Marubeni-Itochu Steel America Plans Osceola, Arkansas, Flat-Rolled Steel Operations
04/25/2026
Corderill Plans Meridian, Mississippi, Operations
04/25/2026
Ferrara Candy Plans Orangeburg County, South Carolina, Production Operations
04/25/2026
Blue Ops Plans Valdosta, Georgia, Manufacturing Operations
04/25/2026
Virginia Transformer Expands Rincon, Georgia, Production Operations
04/25/2026
AbbVie Plans Durham, North Carolina, Pharmaceutical Manufacturing Operations
04/24/2026
Air Liquide Plans St. James Parish, Louisiana, Production Operations
04/24/2026
Most Read
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
40th Annual Corporate and 22nd Annual Consultant Site Selection Survey Results
Q1 2026
-
Where Workforce Capacity Is Being Built — and Where It’s Being Deployed
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026